文献速递胸部肿瘤

Quavonlimab联合帕博利珠单抗一线治疗晚期NSCLC的安全性与疗效

Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2020-12-02

这项I期研究评估了新型抗CTLA-4抗体Quavonlimab联合帕博利珠单抗在晚期实体瘤及一线晚期NSCLC中的安全性和疗效。剂量递增阶段未达到最大耐受剂量,剂量确认阶段各方案均观察到疗效,ORR为27.5%-40.0%。Quavonlimab 25 mg Q6W联合帕博利珠单抗疗效相似且安全性更优,被选为II期推荐剂量。

要点

  • Quavonlimab联合帕博利珠单抗在NSCLC中显示出抗肿瘤活性,ORR为27.5%-40.0%。
  • 25 mg Q6W方案疗效与其他剂量/ schedule相似,且安全性更优,被选为RP2D。
  • PD-L1表达和循环CD4+细胞总数与ORR相关。

核心结论

  • Quavonlimab 25 mg Q6W联合帕博利珠单抗在所有评估的剂量/方案中疗效相似且安全性更优,被选为II期推荐剂量。

研究设计与样本

  • 剂量递增阶段:Quavonlimab 25 mg、75 mg或200 mg单药初始治疗,随后同剂量联合帕博利珠单抗每3周一次。
  • 剂量确认阶段:一线Quavonlimab 25 mg Q3W(A组)、25 mg Q6W(B组)、75 mg Q6W(C组)或75 mg Q3W(E组)联合帕博利珠单抗。

主要发现

  • 剂量递增阶段未达到最大耐受剂量。
  • 3-5级治疗相关不良事件发生率:剂量递增阶段队列1、2、3分别为0%、23.5%、75.0%;剂量确认阶段A、B、C、E组分别为35.0%、30.0%、35.0%、57.1%。
  • NSCLC患者中各剂量/方案均观察到疗效,ORR分别为A组40.0%(95%CI 24.9-56.7)、B组37.5%(95%CI 22.7-54.2)、C组27.5%(95%CI 14.6-43.9)、E组35.7%(95%CI 12.8-64.9)。
  • PD-L1表达和循环CD4+细胞总数与ORR相关。

关键数值与推荐

  • Quavonlimab 25 mg Q6W联合帕博利珠单抗被选为II期推荐剂量。
  • NSCLC患者中ORR:A组40.0%(95%CI 24.9-56.7),B组37.5%(95%CI 22.7-54.2),C组27.5%(95%CI 14.6-43.9),E组35.7%(95%CI 12.8-64.9)。

临床怎么用

  • 对于一线晚期NSCLC,Quavonlimab 25 mg Q6W联合帕博利珠单抗可作为后续研究的推荐方案。
  • 治疗期间需监测治疗相关不良事件,尤其是3-5级不良事件。

局限性

  • 本研究为I期研究,样本量有限,需进一步验证。
  • 疗效与PD-L1表达和CD4+细胞的相关性为探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Quavonlimab (MK-1308), a novel anti-CTLA-4 antibody, in combination with pembrolizumab was investigated in a phase I study. PATIENTS AND METHODS: Dose-escalation (DE) phase: patients with advanced/metastatic solid tumors received an initial flat dose of quavonlimab as monotherapy [25 mg (cohort 1), 75 mg (cohort 2), or 200 mg (cohort 3)] followed by four treatments of the same quavonlimab dose plus pembrolizumab every 3 weeks (Q3W). Dose-confirmation phase (DC): patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) received first-line quavonlimab [25 mg Q3W (arm A), 25 mg Q6W (arm B), 75 mg Q6W (arm C), or 75 mg Q3W (arm E)] plus pembrolizumab. Primary objectives were safety and tolerability and establishment of the recommended phase II dose (RP2D) of quavonlimab when used with pembrolizumab. Objective response rate (ORR) was a secondary endpoint. Efficacy based on PD-L1 expression, tumor mutational burden (TMB), and changes in circulating CD4+/CD8+ cells were exploratory endpoints. RESULTS: Thirty-nine patients were enrolled in DE [n = 14 (cohort 1); n = 17 (cohort 2); n = 8 (cohort 3)] and 134 in DC [n = 40 (arm A); n = 40 (arm B); n = 40 (arm C); n = 14 (arm E)]. Maximum-tolerated dose was not reached. Grade 3-5 treatment-related adverse events (AEs; graded according to NCI CTCAE v4.03) occurred in 0%, 23.5%, and 75.0% of patients in DE cohorts 1, 2, and 3, respectively, and 35.0%, 30.0%, 35.0%, and 57.1% of patients in DC arms A, B, C, and E, respectively. Efficacy was observed at all dose levels/schedules in patients with NSCLC. ORRs were 40.0% [95% confidence interval (CI), 24.9-56.7; arm A], 37.5% (95% CI, 22.7-54.2; arm B), 27.5% (95% CI, 14.6-43.9; arm C), and 35.7% (95% CI, 12.8-64.9; arm E). PD-L1 expression and total number of circulating CD4+ cells correlated with ORR. CONCLUSIONS: Quavonlimab 25 mg Q6W plus pembrolizumab demonstrated similar efficacy and a better safety profile among all quavonlimab doses/schedules evaluated; this regimen was the chosen RP2D.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Perets R, Bar J, Rasco DW, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2020. PMID: 33276076. doi:10.1016/j.annonc.2020.11.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。